Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krumpe, P.
Right arrow Articles by Affrime, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krumpe, P.
Right arrow Articles by Affrime, M. B.
(Chest. 1999;116:369-374.)
© 1999 American College of Chest Physicians

The Penetration of Ceftibuten Into the Respiratory Tract*

Peter Krumpe, MD, FCCP; Chin-Chung Lin, PhD; Elaine Radwanski, PhD; Mitchell N. Cayen, PhD and Melton B. Affrime, PharmD

* From the Departments of Pulmonary and Critical Care Medicine (Dr. Krumpe), VA Medical Center, Reno, NV; and Departments of Drug Metabolism and Pharmacokinetics (Drs. Lin, Radwanski, and Cayen), and the Department of Clinical Pharmacology (Dr. Affrime), Schering-Plough Research Institute, Kenilworth, NJ.

Correspondence to: Peter Krumpe, MD, FCCP, Departments of Pulmonary and Critical Care Medicine, Veterans Administration Medical Center, 1000 Locust Street, Reno, NV 89520

Study objective: To determine the penetration of ceftibuten into various respiratory tissues and fluids.

Design: Single-dose, open-label, pharmacokinetic study.

Setting: Veterans Administration Medical Center.

Patients: Twelve hospitalized men aged 34 to 75 years with a variety of noninfectious pulmonary symptoms/diseases.

Interventions: Patients received a single oral dose of ceftibuten, 200 mg, prior to undergoing diagnostic fiberoptic bronchoscopy. Plasma samples for the determination of ceftibuten concentrations were collected pretreatment and up to 12 h postdosing. Nasal secretions, tracheal secretions, BAL fluid, and lung tissue from a biopsy were obtained at bronchoscopy from 2 to 7 h postdosing.

Measurements and results: Mean pharmacokinetic parameters for ceftibuten in plasma were the following: maximum observed plasma concentration (Cmax), 8.77 µg/mL; time to reach Cmax, 2.2 h; area under the plasma concentration-time curve extraploated to infinity, 49.21 µg/h/mL; and terminal elimination half-life, 3.17 h. These parameters were similar to those obtained in studies using healthy volunteers. Mean penetration of ceftibuten into nasal, tracheal, and bronchial secretions was 47%, 50%, and 30%, respectively. Mean penetration into BAL fluid was 81%, whereas penetration into lung tissue was 39%. No patient experienced any adverse effects related to ceftibuten.

Conclusions: Ceftibuten penetrates well into various tissues and fluids of the upper and lower respiratory tracts. The results support the activity of ceftibuten in the treatment of upper and lower respiratory tract infections.

Key Words: ceftibuten • pharmacokinetics • respiratory tract • tissue penetration






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.